Zhengzhou University
Clinical trials sponsored by Zhengzhou University, explained in plain language.
-
New hope for brain cancer: CAR-T and stem cell combo trial launches
Disease control Not yet recruitingThis study tests a combination of four treatments for primary central nervous system lymphoma (PCNSL), a rare and aggressive brain cancer. The approach uses the patient's own immune cells (CAR-T cells) and stem cells, plus two targeted drugs. The goal is to see if this powerful m…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 24, 2026 07:51 UTC
-
New cocktail of three drugs aims to tackle rare lymphoma
Disease control Not yet recruitingThis study tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. The trial will enroll 50 adults aged 18-75 with advanced disease who haven't had treatment yet. Re…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New combo therapy offers hope for hard-to-treat lymphoma patients
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to improve remission rates and keep the cancer under control longer. Partic…
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC